New agents in post-remission therapy

被引：1
作者：
Stone, Richard M. [1 ]
机构：
[1] Harvard Univ, Sch Med, Adult Leukemia Program, Boston, MA 02115 USA
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2010年 / 23卷 / 04期
关键词：
acute myeloid leukemia; AML; post-remission; older adults; younger adults; high-dose ara-C; immunotherapy; cell-signaling modulation; ACUTE MYELOID-LEUKEMIA; HIGH-DOSE CYTARABINE; TRANS-RETINOIC ACID; PHASE-III; GROUP-B; CONSOLIDATION THERAPY; COMPLETE REMISSION; CANCER; CHEMOTHERAPY; MUTATIONS;
D O I：
10.1016/j.beha.2010.09.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The choice of post-remission therapy for patients with acute myeloid leukemia (AML) depends on age, response to initial therapy, and on disease-related biology. High-dose ara-C (HIDAC) is the standard chemotherapy-based post-remission treatment for younger AML patients, but diagnostic cytogenetics and genetic features may mandate an allogeneic stem cell transplant. While intensive chemotherapy has little utility, the optimal post-remission therapy for older adults remains unclear, though reduced-intensity conditioning allogeneic stem cell transplant is being used with increasing frequency. (C) 2010 Published by Elsevier Ltd.
引用
收藏
页码：475 / 479
页数：5
相关论文
共 25 条
  • [1] Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720
    Baer, Maria R.
    George, Stephen L.
    Caligiuri, Michael A.
    Sanford, Ben L.
    Bothun, Sandra M.
    Mrozek, Krzysztof
    Kolitz, Jonathan E.
    Powell, Bayard L.
    Moore, Joseph O.
    Stone, Richard M.
    Anastasi, John
    Bloomfield, Clara D.
    Larson, Richard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) : 4934 - 4939
  • [2] Bloomfield CD, 1998, CANCER RES, V58, P4173
  • [3] Bloomfield CD, 1997, CANCER, V80, P2186
  • [4] Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
    Brune, Mats
    Castaigne, Sylvie
    Catalano, John
    Gehlsen, Kurt
    Ho, Anthony D.
    Hofmann, Wolf-Karsten
    Hogge, Donna E.
    Nilsson, Bo
    Or, Reuven
    Romero, Ana I.
    Rowe, Jacob M.
    Simonsson, Bengt
    Spearing, Ruth
    Stadtmauer, Edward A.
    Szer, Jeff
    Wallhult, Elisabeth
    Hellstrand, Kristoffer
    [J]. BLOOD, 2006, 108 (01) : 88 - 96
  • [5] The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA
    Burnett, Alan K.
    Hills, Robert K.
    Green, Claire
    Jenkinson, Sarah
    Koo, Kenneth
    Patel, Yashma
    Guy, Carol
    Gilkes, Amanda
    Milligan, Donald W.
    Goldstone, Anthony H.
    Prentice, Archibald G.
    Wheatley, Keith
    Linch, David C.
    Gale, Rosemary E.
    [J]. BLOOD, 2010, 115 (05) : 948 - 956
  • [6] Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461
    Byrd, JC
    Ruppert, AS
    Mrózek, K
    Carroll, AJ
    Edwards, CG
    Arthur, DC
    Pettenatti, MJ
    Stamberg, J
    Koduru, PRK
    Moore, JO
    Mayer, RJ
    Davey, FR
    Larson, RA
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1087 - 1094
  • [7] CASSILETH PA, 1984, BLOOD, V63, P843
  • [8] DiPersio JF, 2009, BLOOD, V114, P262
  • [9] Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:: interaction with other gene mutations
    Döhner, K
    Schlenk, RF
    Habdank, M
    Scholl, C
    Rücker, FG
    Corbacioglu, A
    Bullinger, L
    Fröhling, S
    Döhner, H
    [J]. BLOOD, 2005, 106 (12) : 3740 - 3746
  • [10] ESTEY EH, 1990, LEUKEMIA, V4, P95
123